Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEER-2 phase 3 trial of RGN-259 ophthalmic solution for neurotrophic keratopathy
2024-518969-98-00Phase 3Authorised
- Sponsor
- ReGenTree
- Start
- Nov 2025
- Modality
- Peptides
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in neurotrophic keratitis (NK) comparing RGN-259 ophthalmic solution with Placebo ophthalmic solution (2 arms). Primary endpoint: Complete healing of persistent epithelial defect at Day 29 by central reading center. Planned start Nov 2025; status: authorised.
02
Drugs
timbetasin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on 2024-518969-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518969-98-00.